GBS Inc. (GBS) News
Filter GBS News Items
GBS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GBS News Highlights
- For GBS, its 30 day story count is now at 2.
- Over the past 5 days, the trend for GBS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about GBS are BIO, DRUG and LGV.
Latest GBS News From Around the Web
Below are the latest news stories about GBS INC that investors may wish to consider to help them evaluate GBS as an investment opportunity.
Intelligent Bio Solutions Inc. Announces Leading U.K. Container Haulier Switching to Fingerprint Drug Screening System for In-house TestingGoldstar Transport to Remove Urine Testing for Sweat Based TechnologyNEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the "Company”), a life sciences company delivering intelligent, non-invasive, real-time testing solutions, today announced that Goldstar Transport, the UK’s market-leading container haulier, has switched out urine tests for fingerprint drug testing. Goldstar employs approximately 600 LGV drivers, 170 office staff and 40 container lifter s |
GBS Inc. Initiates Company Name Change to Intelligent Bio Solutions Inc. (IBSS) and Announces Key Executive Appointments- Name change to more closely reflect firm’s expanding portfolio of intelligent, efficient, convenient and practical noninvasive and drug testing technologies and products - - Harry Simeonidis appointed as Chief Executive Officer - - David Jenkins and Jason Isenberg appointed to Board of Directors - NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), now Intelligent Bio Solutions Inc. (Nasdaq: IBSS) (the "Company”), a life sciences company developing non-invasive, real-time diagn |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for another overview of the biggest pre-market stock movers for Wednesday as we cover the news behind share movement this morning! |
GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening TechnologyThe transaction further solidifies GBS’ leadership in non-invasive, real-time diagnostic testing with an expanded portfolio and geographical reachGBS’ global footprint includes operations in Australia, United Kingdom and the US NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced it has acquired Intelligent Fingerprinti |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning! |
GBS: Correlation Study CompleteBy John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT Fiscal Year 2022 Operational and Financial Results GBS, Inc. (NASDAQ:GBS) announced fiscal year 2022 financial and operational results for the period ending June 30, 2022 in an August 31 press release and subsequently filed Form 10-K on September 22, 2022. Year to Date 2022 Events ➢ Participation in Roth & Maxim Investor |
GBS Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business Highlights- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition - - Completed collection and analysis in a study with coincidental sampling of oral fluid and blood to evaluate the time-course of glucose in oral fluids - - Company to host conference call & webcast today at 4:30 p.m. ET - NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasi |
GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31Company to Host Conference Call & Webcast at 4:30 p.m. ETNEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the fourth quarter and full year ended June 30, 2022, shortly after the NASDAQ market close on Wednesday, August 31. Management will then host a conference call and |
GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and BloodThe trial is single center, prospective study collecting coincident samples of oral fluids and blood to evaluate the time-course of glucose NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced completion of sample collection and analysis of glucose in oral fluid and blood samples from their clinical study at the Diabete |
GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia CampusNEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that the Company and the University of Newcastle in Australia have selected a site for its proprietary biosensor technology. “Maintaining momentum with our partners at the University of Newcastle has been and will remain a principal objective to generating shareholder |